Showing 1761-1770 of 5643 results for "".
- Nova Eye: 24-Month iTrack Data Demonstrate Real-World Efficacy of Canaloplasty as Both a Standalone and Combined MIGS Procedurehttps://modernod.com/news/nova-eye-24-month-itrack-data-demonstrate-real-world-efficacy-of-canaloplasty-as-both-a-standalone-and-combined-migs-procedure/2479091/Nova Eye Medical is reporting the peer-reviewed publication of 24-month data for its proprietary iTrack minimally invasive glaucoma surgery (MIGS) technology. Published in Clinical Oph
- Magewell Video Capture Devices Help Non-Profit Eyecare Organization Remotely Train Retinal Surgeons Worldwidehttps://modernod.com/news/magewell-video-capture-devices-help-non-profit-eyecare-organization-remotely-train-retinal-surgeons-worldwide/2478975/Telemedicine workflows incorporating live video have taken on dramatically greater importance for surgical education during the COVID-19 pandemic, as doctors reduce non-essential personnel in their operating rooms for the safety of patients and staff. Needing a way to continue its mission of impr
- Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-36-million-series-a-financing-to-advance-development-of-novel-presbyopia-correcting-eye-drop/2478952/Visus Therapeutics announced the close of a $36 million Series A Preferred Stock financing to advance the clinical development program for the company’s lead asset, Brimochol, an investigational drug designed to be a
- Notal Vision Launches First US Home OCT Longitudinal Study with Patient Self-Operated Devicehttps://modernod.com/news/notal-vision-launches-first-us-home-oct-longitudinal-study-with-patient-self-operated-device/2478748/Notal Vision announced that it has initiated the first US-based study using its investigational home-based optical coherence tomography (OCT) platform. The study will evaluate the ability of subjects with wet age-rela
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- Quest Diagnostics’ Self-Collection COVID-19 Test Kit Gets FDA Nod For Emergency Usehttps://modernod.com/news/quest-diagnostics-self-collection-covid-19-test-kit-gets-fda-nod-for-emergency-use/2477851/Quest Diagnostics received emergency use authorization for its self-collection COVID-19 test kit from the FDA, according to a FierceHealthcare report. The co
- Expert: Hospitals Should Prepare For Pent-Up Demand From Non-COVID-19 Patientshttps://modernod.com/news/expert-hospitals-should-prepare-for-pent-up-demand-from-non-covid-19-patients/2477848/While much of the focus has been on “flattening the curve” when it comes to COVID-19, experts warn hospitals should be prepared for another potential surge: pent-up demand for deferred care, according to a FierceHealthcare
- Gilead Inks Non-US Deals With Five Generic Drugmakers to Expand Supply of COVID-19 Drug Remdesivirhttps://modernod.com/news/gilead-inks-non-us-deals-with-five-generic-drugmakers-to-expand-supply-of-covid-19-drug-remdesivir/2477757/Gilead Sciences said it has signed non-exclusive voluntary licensing agreements with Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan to manufacture COVID-19 treatment remdesivir for distribution in 127 countries. According to Gilead, the list consists of nearly all low
- UK Surpasses Italy In Recorded Coronavirus Deaths, Now Leads Europe In Fatalitieshttps://modernod.com/news/uk-surpasses-italy-in-recorded-coronavirus-deaths-now-leads-europe-in-fatalities/2477715/Over 32,000 people have died from the new coronavirus in the United Kingdom, according to the Office for National Statistics, marking the first time in the pandemic that it has led Europe in the number of deaths, according to an NPR
- Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseaseshttps://modernod.com/news/boehringer-ingelheim-partners-with-inflammasome-therapeutics-to-develop-novel-therapies-for-patients-with-retinal-diseases/2476903/Boehringer Ingelheim and Inflammasome Therapeutics announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelhei